V
39.15
2.44 (6.65%)
| Previous Close | 36.71 |
| Open | 36.40 |
| Volume | 849,757 |
| Avg. Volume (3M) | 779,804 |
| Market Cap | 3,034,109,440 |
| Price / Earnings (Forward) | 45.87 |
| Price / Sales | 7.33 |
| Price / Book | 2.69 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2024 |
| Profit Margin | -2.18% |
| Operating Margin (TTM) | 10.53% |
| Diluted EPS (TTM) | -0.130 |
| Quarterly Revenue Growth (YOY) | 28.60% |
| Total Debt/Equity (MRQ) | 1.68% |
| Current Ratio (MRQ) | 5.07 |
| Operating Cash Flow (TTM) | 66.12 M |
| Levered Free Cash Flow (TTM) | 57.26 M |
| Return on Assets (TTM) | 1.07% |
| Return on Equity (TTM) | -0.83% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Veracyte, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.5
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.50 |
|
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 0.79% |
| % Held by Institutions | 104.38% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 46.00 (UBS, 17.50%) | Buy |
| Median | 40.00 (2.17%) | |
| Low | 28.00 (Morgan Stanley, -28.48%) | Sell |
| Average | 39.86 (1.81%) | |
| Total | 5 Buy, 1 Hold, 1 Sell | |
| Avg. Price @ Call | 36.76 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 05 Dec 2024 | 37.00 (-5.49%) | Hold | 42.84 |
| 07 Nov 2024 | 38.00 (-2.94%) | Buy | 37.34 | |
| Morgan Stanley | 18 Nov 2024 | 28.00 (-28.48%) | Sell | 36.71 |
| Scotiabank | 08 Nov 2024 | 44.00 (12.39%) | Buy | 36.48 |
| Needham | 07 Nov 2024 | 44.00 (12.39%) | Buy | 37.34 |
| UBS | 07 Nov 2024 | 46.00 (17.50%) | Buy | 37.34 |
| 16 Oct 2024 | 43.00 (9.83%) | Buy | 34.72 | |
| Leerink Partners | 17 Oct 2024 | 40.00 (2.17%) | Buy | 34.31 |
| Guggenheim | 10 Oct 2024 | 40.00 (2.17%) | Buy | 32.27 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Dec 2024 | Announcement | Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines |
| 06 Nov 2024 | Announcement | Veracyte Announces Third Quarter 2024 Financial Results |
| 30 Oct 2024 | Announcement | Veracyte to Participate in Upcoming Investor Conferences |
| 16 Oct 2024 | Announcement | Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024 |
| 02 Oct 2024 | Announcement | New Data Presented at ASTRO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |